{"id":127057,"date":"2026-09-07T14:39:06","date_gmt":"2026-09-07T14:39:06","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/127057\/"},"modified":"2026-09-07T14:39:06","modified_gmt":"2026-09-07T14:39:06","slug":"novartis-just-lost-a-potential-6-billion-drug-opportunity","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/127057\/","title":{"rendered":"Novartis Just Lost a Potential $6 Billion Drug Opportunity"},"content":{"rendered":"<p>Novartis AG (<a href=\"https:\/\/www.gurufocus.com\/stock\/NVS\/summary\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">NVS<\/a>, <a href=\"https:\/\/www.gurufocus.com\/stock\/NVS\/financials\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Financials<\/a>) has received a sobering <a href=\"https:\/\/www.reuters.com\/legal\/litigation\/novartis-shares-down-failed-cholesterol-drug-study-increases-pipeline-pressure-2026-09-07\/?utm_source=chatgpt.com\" target=\"_blank\" rel=\"nofollow noopener\">reminder of how quickly billions of dollars in prospective<\/a> medicine sales can disappear. Its experimental cholesterol drug pelacarsen failed in a high-profile late-stage study.<\/p>\n<p>But the medicine failed to provide the hoped-for reduction in major cardiovascular events. That&#8217;s important because expectations were sky-high<\/p>\n<p>If effective, analysts had predicted the treatment might one day produce yearly sales of $3 billion to $6 billion. That chance now looks much less plausible.<\/p>\n<p>There is always that danger in drug development. One trial can transform the whole financial picture for a treatment after years of research and hundreds of millions of dollars. Novartis is big enough to take a clinical failure.<\/p>\n<p>But the loss of a possible multibillion-dollar product means the remainder of its pipeline has to produce for future development. That is what investors will be looking at next.<\/p>\n<p>The question is no longer what pelacarsen could have been. It&#8217;s the late-stage Novartis medication that delivers the growth investors were hoping for.<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis AG (NVS, Financials) has received a sobering reminder of how quickly billions of dollars in prospective medicine&hellip;\n","protected":false},"author":2,"featured_media":127058,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[101,62017,3275,1202,206,9959],"class_list":["post-127057","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-article","tag-faizan-farooque","tag-gurufocus","tag-news","tag-novartis","tag-nvs"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117230276696906149","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127057","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=127057"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/127057\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/127058"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=127057"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=127057"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=127057"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}